The Nifty 50 extended its winning streak to a fourth consecutive session, closing at 23,774 with a gain of 390 points, according to Prime Research. The index opened 44 points higher and built on its gains in the first half, hitting an intraday high of 24,429 before profit booking emerged in the latter part of the session. Notably, the index experienced a massive 200-point surge during the closing auction session (CAS), driven by a greater-than 1% movement across 10 to 12 Nifty stocks. NSE cash market volumes fell 6% from the previous session, while the Indian rupee strengthened 4 paise to close at 95.35, supported by declining crude oil prices after U.S. President Donald Trump announced fresh U.S.-Iran talks.
Apollo Hospitals Enterprises shares gained 0.54% to ₹8,868 from ₹8,820 in the latest trading session, according to HDFC SKY reports. The healthcare stock led healthcare sector gains despite broader market weakness, demonstrating continued investor confidence in the healthcare provider's performance trajectory. The stock's performance comes amid mixed market conditions where Nifty 50 declined 1.06% while Nifty Microcap 250 bucked the trend to gain 0.49%. Among Nifty 50 constituents, Grasim, TCS and IndiGo led the gainers, while Apollo Hospitals, Sun Pharma and Maruti were the key laggards.
The healthcare sector's positive performance was part of a broader market session that showed strong momentum with all major sectoral indices closing in the green except Media. IT, private banks, and FMCG were the top performers, while broader markets also firmed up alongside the benchmark, with both the Nifty Midcap 100 and Smallcap 100 advancing 1.2% and 1.3%, respectively. Market breadth was strong, with the BSE advance-decline ratio at 1.82, signaling continued buying interest in the midcap and smallcap space for a second straight day. Sectoral performance remained broadly positive, with IT, private banks, and FMCG leading the gains, while the Indian rupee strengthened 4 paise to close at 95.35, supported by sustained foreign inflows into both equity and debt markets.
The company has demonstrated consistent growth in its financial performance over recent years, as reported by Moneycontrol.com. Revenue on a consolidated basis increased from ₹14,662.60 crore in March 2022 to ₹25,228.50 crore in March 2026, marking a significant upward trend. Net profit also followed a similar trajectory, growing from ₹1,101.10 crore in March 2022 to ₹1,957.80 crore in March 2026. This reflects robust financial health and operational efficiency across the healthcare provider's operations.
For the quarter-ending March 2026, consolidated revenue was ₹6,605.50 crore, an increase from ₹5,592.20 crore in the quarter-ending March 2025, according to Moneycontrol.com. Net profit for the same period rose from ₹404.00 crore to ₹541.20 crore. Earnings Per Share (EPS) also improved significantly, from ₹27.10 in March 2025 to ₹36.82 in March 2026, demonstrating continued operational strength and supporting the stock's strong performance in the current market session.
Key financial ratios indicate a healthy position for Apollo Hospitals Enterprises, as reported by Moneycontrol.com. The Debt to Equity ratio stands at 0.60 as of March 2026, reflecting manageable debt levels. Return on Equity (ROE) was 20.48% for the same period, suggesting efficient utilization of shareholder funds. The P/E ratio for March 2026 was 54.94, and the P/B ratio was 11.27. The company has declared a final dividend of ₹10.00 per share (200%) with an effective date of August 14, 2026, and an interim dividend of ₹10.00 per share (200%) with an effective date of February 16, 2026.
Other corporate announcements include a shareholders meeting scheduled for August 25, 2026, and the annual report submission on August 1, 2026, according to Moneycontrol.com. The company's strong financial performance and consistent dividend declarations reflect its solid operational foundation and commitment to shareholder returns in the competitive healthcare sector. Looking ahead, market participants will be watching whether the healthcare sector's leadership can broaden beyond Apollo Hospitals to include other healthcare constituents, while the broader market's positive momentum suggests continued selective buying interest across sectors.
